Menu
"Today is the day we’ve been waiting for," RWC-340B President Shannon Stephenson said about HRSA's 340B contract cease and desist letters yesterday to six drug manufacturers.

Drug Makers Defensive, Providers Thrilled About HRSA’s 340B Contract Pharmacy Letters

In Federal, Regulatory872 Views Tom Mirga

Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA).

Groups and individuals representing 340B covered entities, meanwhile, praised HRSA for taking a stand against the six drug makers—AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics.

Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA). Groups and individuals representing 340B covered entities, meanwhile, praised HRSA for taking a stand against the six drug makers—AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

×

*Sign up for news summaries and alerts from 340B Report

Site Footer